Clinical Trial Update: Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level [Phase 2]

View source ↗

Summary

Phase 2 trial results of brentuximab vedotin (SGN-35) in patients with mycosis fungoides/cutaneous T-cell lymphoma with variable CD30 expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Non-hodgkin Lymphoma
• Sezary Syndrome

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Youn Kim | Conditions: Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-05